EBS
Emergent BioSolutions Inc.Company with tickers: EBS
CIK
1367644
CUSIP
29089Q105
Shares Outstanding
51,596,296
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $222,200,000 | USD | 2025-03-31 | 10-Q | 2026-05-01 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $15,100,000 | USD | 2025-03-31 | 10-Q | 2026-05-01 |
| Operating Income | $49,900,000 | USD | 2025-03-31 | 10-Q | 2026-05-01 |
| Net Income | $68,000,000 | USD | 2025-03-31 | 10-Q | 2026-05-01 |
| EPS (Basic) | $1.25 | USD/shares | 2025-03-31 | 10-Q | 2026-05-01 |
| EPS (Diluted) | $1.19 | USD/shares | 2025-03-31 | 10-Q | 2026-05-01 |